Cristian Topriceanu

211 posts

Cristian Topriceanu

@CTopriceanu

Innovating for🫀health (#whyCMR, #epi, #Multiomics) | IM resident @MayoMN_IMRES | post-doc @brighamwomens | MBBS PhD @ucl | biomed engineering @imperialcollege

United States เข้าร่วม Aralık 2020

299 กำลังติดตาม297 ผู้ติดตาม

ทวีตที่ปักหมุด

Cristian Topriceanu@CTopriceanu·30 Mar

I am truly humbled to receive the William W. Parmley Award. This acknowledgment reinforces my commitment to excellence in #Cardiology, and I am eager to continue contributing meaningfully to the @ACCinTouch/ @JACCJournals community. Special thanks to my mentor @gabycaptur! @MRCLHA @UCL_ICS

JACC Journals@JACCJournals

#JACC has honored 5️⃣ primary authors with the William W. Parmley Young Author Achievement Award, recognizing their exceptional research papers published in the journal. 📎: acc.org/About-ACC/Pres… #ACC25 #TheFaceOfCardiology @CHRLee1212 @safchat @CTopriceanu

English

4.1K

Cristian Topriceanu@CTopriceanu·30 Mar

#ACC26 New Orleans — what a conference. 🎉 The science, the debates, the energy. Unmatched. @JACCJournals @ACCinTouch

Sara Ersözlü, MD, CCK@ErsozluSara

Cardiac imagers coming together at the @JACCJournals reception at #ACC26, Multimodality #whyCMR #whyCCT #EchoFirst #whyPET, subspecialty imaging societies @SCMRorg @Heart_SCCT @ASE360, multinational and transcontinental. @ACCinTouch

English

158

Cristian Topriceanu@CTopriceanu·30 Mar

🚨 #ACC26 | SMART-DECISION In 2,540 stable post-#MI pts (LVEF ≥40%, no #HF) on β-blockers ≥1yr, discontinuation vs continuation: 7.2% vs 9.0% composite (#death/#MI/#HF hosp); HR 0.80 (95% CI 0.57–1.13) — noninferior (p=0.001). @JACCJournals @ACCinTouch

English

220

Cristian Topriceanu@CTopriceanu·30 Mar

#ACC26 | ESSENCE-CTA: Olezarsen drove TG ↓64%, remnant cholesterol ↓72%, ApoB ↓16% vs placebo — but noncalcified coronary plaque changed –5.35% vs –3.91% (placebo-adjusted diff +2.98%, p=0.36). No difference in any plaque subtype at 12 months. ❌ @JACCJournals @ACCinTouch

English

640

Cristian Topriceanu@CTopriceanu·30 Mar

#ACC26 PROTECT H2H: First head-to-head RCT of embolic protection in #TAVR (n=522). 30-day composite of all-cause #death, #stroke and acute kidney failure: 4.9% (Emboliner) vs. 5.0% (Sentinel). Stroke: 2.0% vs. 2.1%. Particle capture: 1,575 vs. 801. Placement success: 96% vs. 87%. @JACCJournals @ACCinTouch

English

182

Cristian Topriceanu@CTopriceanu·30 Mar

#ACC26 PRO-TAVI: In #TAVI pts with #CAD, deferring #PCI vs routine pre-#TAVI #PCI showed 24% vs 26% 1-yr composite events (HR 0.89; p=0.0008 for non-inferiority). Deferral = non-inferior. ✅ @JACCJournals @ACCinTouch

English

125

Cristian Topriceanu@CTopriceanu·29 Mar

#ACC26 🔥 CADENCE trial #Sotatercept in #CpcPH #HFpEF (n=164): PVR changed −0.67 WU with sotatercept 0.3mg/kg, −0.33 WU with sotatercept 0.7mg/kg, and +0.26 WU with placebo. Placebo-adjusted reductions: −1.02 WU (p=0.004) and −0.75 WU (p=0.024). @JACCJournals @ACCinTouch

English

196

Cristian Topriceanu@CTopriceanu·29 Mar

#ACC26 SPIRIT-HF: Spironolactone vs placebo in 730 #HFpEF/#HFmrEF — 12.7 vs 10.8 events/100 pt-years for #HF hospitalization + #CV death at 24mo (ns). More hyperkalemia, hypotension & renal events with spironolactone ❌ @JACCJournals @ACCinTouch

English

214

Cristian Topriceanu@CTopriceanu·29 Mar

🚨 #ACC26 SCOUT-HCM: Mavacamten vs placebo in adolescents with obstructive #HCM (n=44, 28 wks) — LVOT gradient −48.5 vs −0.5 mmHg (diff −48 mmHg; p<0.001). No LVEF <50%. No deaths. @JACCJournals @ACCinTouch

English

149

Cristian Topriceanu@CTopriceanu·29 Mar

#ACC26 VESALIUS-CV: In #diabetic patients without significant atherosclerosis, #evolocumab reduced #MACE (#CHD death/#MI/ischemic #stroke): 5% vs 7% (HR 0.7) & all-cause mortality: 8% vs 10% (HR 0.8) vs placebo. @JACCJournals @ACCinTouch

English

139

Cristian Topriceanu@CTopriceanu·29 Mar

🔥 #ACC26 EZ-PAVE: #LDL <55 vs <70 mg/dL in #ASCVD for #SecondaryPrevention. #CVdeath, #MI, #stroke composite 6.6% vs 9.7% (HR 0.67; 95% CI 0.52 to 0.86; p=0.002). Similar safety. @JACCJournals @ACCinTouch

English

126

Cristian Topriceanu@CTopriceanu·29 Mar

#ACC26 KARDINAL: Monthly tonlamarsen vs single dose in 198 pts with uncontrolled #hypertension. Angiotensinogen: -67.2% vs -23.0% (p<0.0001) ✅ Office SBP: -6.7 vs -6.7 mmHg (p=0.97) ❌ More #RAAS suppression. Same BP. @JACCJournals @ACCinTouch

English

1.8K

Cristian Topriceanu@CTopriceanu·28 Mar

#ACC26 CHAMPION-AF: 3,000 #AF patients were randomized to #LAAclosure vs #NOAC. #CV death/#stroke/embolism occurred in 5.7% vs 4.8% (noninferior, p<0.001). ✅ Non-procedure #bleeding occurred in 10.9% vs 19.0%, HR 0.55 (p<0.001), superior. ✅ @JACCJournals @ACCinTouch

English

166

Cristian Topriceanu@CTopriceanu·28 Mar

#ACC26 🔥 HI-PEITHO — positive trial. Catheter-directed #fibrinolysis + #anticoagulation vs #anticoagulation alone in intermediate-risk #PE: 7-day composite of #PE-related death, cardiorespiratory decompensation, or symptomatic #PE recurrence: 4.0% vs 10.3% (RR 0.39; P=0.005). The bar for anticoagulation alone just got higher. @JACCJournals @ACCinTouch

English

203

Cristian Topriceanu@CTopriceanu·28 Mar

#ACC26 STEMI-DTU: TV-mAFP + 30-min delayed #PCI vs. immediate #PCI in anterior #STEMI (no shock). Infarct size/LV mass: 30.8% vs. 31.9%; p=0.50. ❌ No benefit. ⚠️ More bleeding/vascular complications in unloading arm. @JACCJournals @ACCinTouch

English

153

Cristian Topriceanu@CTopriceanu·27 Mar

CLOSURE-AF: LAAC vs. best medical therapy in high-risk #AF (mean CHA₂DS₂-VASc 5, HAS-BLED 3). Primary composite (#stroke, systemic embolism, major #bleeding, CV/unexplained death): 17 vs 13/100 pt-yrs. #LAAC failed noninferiority (p=0.44). @JACCJournals @ACCinTouch #ACC26

English

Cristian Topriceanu@CTopriceanu·27 Mar

OTHER 1) HI-PEITHO* — Catheter-directed thrombolysis vs anticoagulation alone in intermediate-high-risk PE 2) SirPAD* — Sirolimus-coated balloon for infra-inguinal PAD (phase 3) 3) Dig-RHD* — Digoxin vs placebo in rheumatic heart disease

English

121

Cristian Topriceanu@CTopriceanu·27 Mar

HYPERTENSION 1) KARDINAL* — Tonlamarsen vs placebo for uncontrolled hypertension (phase 2) 2) GoFreshRx* — DASH-patterned grocery delivery to reduce BP in treated hypertension

English

Cristian Topriceanu@CTopriceanu·27 Mar

It has been a great year for the @ACCinTouch under the leadership of Prof. @ChrisKramerMD and for #JACC under the leadership of Prof. @hmkyale. As a @JACCJournals Ambassador, I'll be posting key takeaways from #ACC26. Here's my must-watch list (*=RCT):

English

181

ค้นพบ

@JACCJournals @ACCinTouch @ChrisKramerMD @hmkyale @elonmusk @BarackObama @taylorswift13 @cristiano